Head and Neck Cancer Drugs Market Size, Share, and Trends 2024 to 2034

The global head and neck cancer drugs market size is calculated at USD 2.05 billion in 2025 and is forecasted to reach around USD 4.06 billion by 2034, accelerating at a CAGR of 7.89% from 2025 to 2034. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.

  • Last Updated : April 2025
  • Report Code : 1474
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Head and Neck Cancer Drugs Market 

5.1. COVID-19 Landscape: Head and Neck Cancer Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Head and Neck Cancer Drugs Market, By Treatment

8.1. Head and Neck Cancer Drugs Market, by Treatment Type

8.1.1. Targeted Therapy

8.1.1.1. Market Revenue and Forecast

8.1.2. Chemotherapy

8.1.2.1. Market Revenue and Forecast

8.1.3. Radiation Therapy

8.1.3.1. Market Revenue and Forecast

8.1.4. Immunotherapy

8.1.4.1. Market Revenue and Forecast

Chapter 9. Global Head and Neck Cancer Drugs Market, By Sales Channel

9.1. Head and Neck Cancer Drugs Market, by Sales Channel

9.1.1. Retail Pharmacies

9.1.1.1. Market Revenue and Forecast

9.1.2. Hospital Pharmacies

9.1.2.1. Market Revenue and Forecast

9.1.3. Online Pharmacies

9.1.3.1. Market Revenue and Forecast

Chapter 10. Global Head and Neck Cancer Drugs Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Treatment

10.1.2. Market Revenue and Forecast, by Sales Channel

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Treatment

10.1.3.2. Market Revenue and Forecast, by Sales Channel

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Treatment

10.1.4.2. Market Revenue and Forecast, by Sales Channel

10.2. Europe

10.2.1. Market Revenue and Forecast, by Treatment

10.2.2. Market Revenue and Forecast, by Sales Channel

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Treatment

10.2.3.2. Market Revenue and Forecast, by Sales Channel

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Treatment

10.2.4.2. Market Revenue and Forecast, by Sales Channel

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Treatment

10.2.5.2. Market Revenue and Forecast, by Sales Channel

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Treatment

10.2.6.2. Market Revenue and Forecast, by Sales Channel

10.3. APAC

10.3.1. Market Revenue and Forecast, by Treatment

10.3.2. Market Revenue and Forecast, by Sales Channel

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Treatment

10.3.3.2. Market Revenue and Forecast, by Sales Channel

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Treatment

10.3.4.2. Market Revenue and Forecast, by Sales Channel

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Treatment

10.3.5.2. Market Revenue and Forecast, by Sales Channel

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Treatment

10.3.6.2. Market Revenue and Forecast, by Sales Channel

10.4. MEA

10.4.1. Market Revenue and Forecast, by Treatment

10.4.2. Market Revenue and Forecast, by Sales Channel

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Treatment

10.4.3.2. Market Revenue and Forecast, by Sales Channel

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Treatment

10.4.4.2. Market Revenue and Forecast, by Sales Channel

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Treatment

10.4.5.2. Market Revenue and Forecast, by Sales Channel

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Treatment

10.4.6.2. Market Revenue and Forecast, by Sales Channel

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Treatment

10.5.2. Market Revenue and Forecast, by Sales Channel

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Treatment

10.5.3.2. Market Revenue and Forecast, by Sales Channel

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Treatment

10.5.4.2. Market Revenue and Forecast, by Sales Channel

Chapter 11. Company Profiles

11.1. AstraZeneca PLC

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Bristol-Myers Squibb Company

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Eli Lilly and Company

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Fortress Biotech, Inc

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. F. Hoffmann-La Roche Ltd.

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Immutep Limited

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Merck & Co., Inc.

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Merck KGaA

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Novartis AG

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. Pfizer Inc.

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global head and neck cancer drugs market size was worth at USD 1.90 billion in 2024 and is predicted to reach USD 4.06 billion by 2034.

The global head and neck cancer drugs market is expected to drive growth at a of 7.89% from 2025 to 2034.

The rising prevalence of head and neck cancer across the globe is the primary factor behind the growth of the global head and neck cancer drugs market.

The major players operating in the head and neck cancer drugs market are AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, Fortress Biotech, Inc, F. Hoffmann-La Roche Ltd., Immutep Limited, Merck & Co., Inc., Merck KGaA, Novartis AG, Pfizer Inc..

North America accounted for the largest market share of the global head and neck cancer drugs market in 2024. The enhanced access to the healthcare services and advanced diagnostic services has resulted in the early screening of the head and neck cancer in North America.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client